New salts and crystals

Abstract

The present disclosure provides novel salts, crystals and co-crystals of certain substituted heterocycle-fused gamma-carbolines described herein, as well as methods of making and using them, and pharmaceutical compositions containing them.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application is an international application claiming priority to and the benefit of U.S. Provisional Application No. 63 / 197,848, filed June 7, 2021, the contents of which are incorporated herein by reference in their entirety.

[0002] Field This disclosure relates to 5-HT 2A and specific salt, crystalline and co-crystalline forms of certain substituted heterocycle-fused gamma-carbolines described herein that are useful for treating disorders involving the receptor, serotonin transporter (SERT), pathways involving the dopamine D1 and / or D2 receptor signaling systems, and / or the μ-opioid receptor, and their preparation. [Background technology]

[0003] Substituted heterocycle-fused gamma-carbolines have been shown to mediate the activity of 5-HT2 receptors, particularly 5-HT 2A These compounds are known to be agonists or antagonists of the 5-HT receptor. These compounds are described in U.S. Pat. Nos. 6,548,493; 7,238,690; 6,552,017; 6,713,471; 7,183,282; U.S. Pat. Re. No. 39680 and U.S. Pat. Re. No. 39679 as being effective in treating 5-HT disorders such as obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, head pain-related conditions, social phobia, gastrointestinal disorders such as gastrointestinal motility disorders, and obesity. 2AIt has been disclosed as a novel compound useful for the treatment of disorders related to receptor modulation. US Patent No. 8,309,722 and US Patent No. 7,081,455 also disclose a method for preparing substituted heterocyclic fused gamma carbolines and the use of these gamma carbolines as serotonin agonists and antagonists useful for controlling and preventing central nervous system disorders such as addictive behaviors and sleep disorders. US Patent No. 8,648,077, US Patent No. 9,199,995 and US Patent No. 9,586,960 also disclose certain solid crystalline salt forms of such compounds. Additional crystalline forms of such compounds are disclosed, for example, in US Patent Application Publication No. 2019 / 0112309, US Patent Application Publication No. 2019 / 0112310, US Patent Application Publication No. 2020 / 0247805 and US Patent Application Publication No. 2020 / 0157100.

[0004] More recently, newer substituted oxo-fused gamma-carbolines have been disclosed that retain many of the unique pharmacological activities of previously disclosed compounds, including serotonin receptor inhibition, SERT inhibition, and dopamine receptor modulation, but have unexpectedly potent activity at the μ-opioid receptor. Such compounds are disclosed, for example, in U.S. Pat. No. 10,245,260, U.S. Pat. No. 10,799,500, U.S. Patent Application Publication No. 2019 / 0330211, U.S. Patent Application Publication No. 2019 / 0345160, U.S. Patent Application Publication No. 2021 / 0145829, and U.S. Patent Application Publication No. 2021 / 0163481, the contents of each of which are incorporated herein by reference in their entirety.

[0005] For example, compound A, shown below, is a potent serotonin 5-HT 2A It is a receptor antagonist and a μ-opioid receptor partial or biased agonist. The compound also interacts with dopamine receptors, particularly the dopamine D1 receptor. [ka]

[0006] It is also believed that compound A can enhance NMDA and AMPA-mediated signal transduction through mTOR pathway through its D1 receptor activity.Thus, compound A is useful for treating or preventing central nervous system disorders, but the art requires additional compounds with this unique biochemical and pharmacological profile, particularly those that may have a pharmacological or pharmacokinetic profile that is subtly altered compared to compound A.

[0007] The preparation of substituted heterocyclic-fused γ-carbolines in free form or in pharma- ceutically acceptable salt form, intermediates used in their preparation, such as enantiomerically pure 2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole-type intermediates, and methods for making the intermediates and substituted heterocyclic-fused γ-carbolines, are disclosed in U.S. Pat. No. 7,183,282, U.S. Pat. No. 8,309,722, U.S. Pat. No. 8,779,139, U.S. Pat. No. 9,315,504, and U.S. Pat. No. 9,751,883, the entire contents of each of which are incorporated herein by reference.

[0008] Furthermore, methods for producing certain fused gamma-carbolines with high purity, yield and economic efficiency are disclosed in WO 2020 / 131895 and US 2022 / 0041600. US 2017 / 0319580 and US 10,799,500 show the preparation of the compound in free base form. Further studies on this free form compound show that it can form crystals that can undesirably trap organic solvents. See WO 2020 / 131895. Only one precursor salt of compound A is specifically shown. WO 2020 / 131895 also shows a solid tosylate salt that discolors on standing but shows acceptable crystallinity.

[0009] There remains a need for pure and stable solid crystalline forms of such compounds to provide the most stable and reliable pharmaceutical formulations with predictable and reproducible bioavailability, especially for oral formulations. Summary of the Invention

[0010] Quick Overview Extensive salt screening was performed to find new salts and polymorphs of Compound A. Compound A has very low solubility in the free base form. It was found to form a brown crystalline powder with a melting event at T peak = 145°C. The free base compound exists as aggregated blocks with a size of less than 20 μm and is slightly hygroscopic. The compound is freely soluble in DMSO, sparingly soluble in ethyl salicylate and anisole, and practically insoluble in most organic solvents and water.

[0011] Surprisingly, it has been found that Compound A does not readily form reproducible salts with common pharma- ceutical acceptable acids.

[0012] A primary salt screen was performed, where the free base compound was studied in different solvent systems and under different conditions, and then systematically screened with a selection of 58 acids under different conditions and with different solvent, co-solvent and anti-solvent systems to identify new potential salt forms. In addition, a co-crystal screen was performed using a variety of conditions with 18 amino acid co-formers. As a result of this extensive screening and experimentation, the most promising crystal forms of compound A were found to be the toluenesulfonate salt, alanine co-crystal, and phenylalanine co-crystal.

[0013] The present disclosure therefore provides novel forms of Compound A that are particularly advantageous for use in the preparation of galenical formulations, together with methods for their preparation and use.

[0014] Further areas of applicability of the present invention will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are intended for purposes of illustration only and are not intended to limit the scope of the invention. [Brief description of the drawings]

[0015] The present invention will become more fully understood from the detailed description and the accompanying drawings, wherein:

[0016] [Figure 1] FIG. 1 shows an X-ray powder diffraction (XRPD) pattern of Compound A toluenesulfonate salt of Example 3. [Diagram 2] FIG. 2 shows the TGA-DSC thermograms of Compound A toluenesulfonate salt of Examples 2-B (top) and 2-A (bottom). [Diagram 3] FIG. 3 shows a TGA-DSC thermogram of Compound A toluenesulfonate salt of Example 3. [Figure 4] FIG. 4 shows an X-ray powder diffraction (XRPD) pattern of Compound A toluenesulfonate salt of Example 5. [Diagram 5] FIG. 5 shows a DSC thermogram of Compound A toluenesulfonate salt of Example 5. [Figure 6] FIG. 6 shows a TG thermogram of the toluenesulfonate salt of Compound A of Example 5. [Figure 7] FIG. 7 shows the X-ray powder diffraction (XRPD) pattern of Compound A oxalate salt. [Figure 8] FIG. 8 shows the TGA-DSC thermograms of Compound A oxalate salt of Examples 2-E (top) and 2-D (bottom). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0017] Detailed Description The following description of the preferred embodiment is merely exemplary in nature and is in no way intended to limit the invention, its application, or uses.

[0018] As used throughout, ranges are used as a shorthand expression to describe any and all values ​​within a range. Any value within the range can be selected as the range terminus. Furthermore, all documents cited herein are incorporated by reference in their entirety. In the event of a discrepancy between a definition in this disclosure and a definition in a cited document, this disclosure controls.

[0019] Unless otherwise specified, all percentages and amounts expressed herein and elsewhere herein should be understood to refer to percent by weight. The amounts stated are based on the active weight of the material.

[0020] In a first embodiment, the present invention provides a solid crystalline salt form of (6bR,10aS)-8-(3-(4-fluorophenoxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (Compound A) (Salt 1), wherein the salt form is selected from hydrochloride, p-toluenesulfonate, tartrate, malate, fumarate, glutamate, oxalate, besylate and ascorbate, and the salt may be chemically stable in air (e.g., does not undergo physical or chemical changes such as a change in appearance or color).

[0021] In further embodiments, the present disclosure provides:

[0022] 1.1 Salt 1, wherein the salt is at least 90% pure, for example at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% pure, for example as shown by LCMS.

[0023] 1.2 Salt 1 or 1.1, wherein the salt contains less than 10% by weight, for example less than 8% by weight, or less than 6% by weight, or less than 5% by weight, or less than 4% by weight, or less than 3% by weight, or less than 2% by weight, or less than 1% by weight, or less than 0.5% by weight, or less than 0.1% by weight, of Compound A in free base form.

[0024] 1.3 Salt 1, or any of 1.1-1.2, wherein the salt contains less than 10% by weight, for example less than 8% by weight, or less than 6% by weight, or less than 5% by weight, or less than 4% by weight, or less than 3% by weight, or less than 2% by weight, or less than 1% by weight, or less than 0.5% by weight, or less than 0.1% by weight, of compound A in other salt forms.

[0025] 1.4 Salt 1, or any of 1.1-1.3, wherein the salt contains less than 10% by weight, for example less than 8% by weight, or less than 6% by weight, or less than 5% by weight, or less than 4% by weight, or less than 3% by weight, or less than 2% by weight, or less than 1% by weight, or less than 0.5% by weight, or less than 0.1% by weight of p-toluenesulfonic acid, tartaric acid, malic acid, fumaric acid, glutamic acid, oxalic acid, benzenesulfonic acid or ascorbic acid.

[0026] 1.5 Salt 1, or any of 1.1-1.4, wherein the salt contains less than 10% by weight of free solvent (e.g. other than the solvent contained in the solvated crystalline form), for example less than 8% by weight, or less than 6% by weight, or less than 5% by weight, or less than 4% by weight, or less than 3% by weight, or less than 2% by weight, or less than 1% by weight, or less than 0.5% by weight, or less than 0.1% by weight.

[0027] 1.6 Salt 1, or any of 1.1-1.5, wherein the salt contains less than 10% by weight, e.g., less than 8% by weight, or less than 6% by weight, or less than 5% by weight, or less than 4% by weight, or less than 3% by weight, or less than 2% by weight, or less than 1% by weight, or less than 0.5% by weight, or less than 0.1% by weight, of synthetic precursors or by-products from the synthetic method used to prepare Compound A in free base form.

[0028] 1.7 Salt 1, or any of 1.1-1.6, wherein the salt is in a homogeneous crystalline form, e.g., free or substantially free of other crystalline forms or polymorphic or amorphous forms of Compound A, e.g., free or substantially free of other crystalline forms or polymorphic forms or amorphous forms, e.g., containing less than 10% by weight, preferably less than about 5% by weight, more preferably less than about 2% by weight, even more preferably less than about 1% by weight, even more preferably less than about 0.1% by weight, and most preferably less than about 0.01% by weight.

[0029] 1.8 Salt 1 or any of 1.1 to 1.7, wherein the salt is a p-toluenesulfonate salt.

[0030] 1.9 Salt 1 or any of 1.1 to 1.7, wherein the salt is a hydrochloride salt.

[0031] 1.10 Salt 1 or any of 1.1 to 1.7, wherein the salt is a tartrate salt.

[0032] 1.11 Salt 1 or any of 1.1 to 1.7, wherein the salt is a malate salt.

[0033] 1.12 Salt 1 or any of 1.1 to 1.7, wherein the salt is a fumarate salt.

[0034] 1.13 Salt 1 or any of 1.1 to 1.7, wherein the salt is a glutamate salt.

[0035] 1.14 Salt 1 or any of 1.1 to 1.7, wherein the salt is an oxalate salt.

[0036] 1.15 Salt 1 or any of 1.1 to 1.7, wherein the salt is an ascorbate salt.

[0037] 1.16 Salt 1 or any of 1.1 to 1.7, wherein the salt is a benzenesulfonate salt.

[0038] 1.17 Salt 1, or any of 1.1-1.16, wherein the salt comprises Compound A free base and an acid counterion (e.g., p-toluenesulfonate anion) in a 1:1 molar ratio (i.e., the monotosylate salt).

[0039] 1.18 Salt 1, or any of 1.1-1.16, wherein the salt comprises Compound A free base and an acid counterion (e.g., p-toluenesulfonate anion) in a molar ratio of 1:2 or 1:3.

[0040] 1.19 Any of salts 1, or 1.1-1.18, wherein the salt is formed by reacting the free base form of compound A with an acid (e.g., p-toluenesulfonic acid) in a molar ratio of 1:0.9 to 1:5, for example, 1:0.9 to 1:3, or 1:0.9 to 1:1.5, or 1:0.9 to 1:1.2, or 1:0.9 to 1:1.1, or about 1:1.

[0041] 1.20 Salt 1, or any of 1.1-1.19, wherein the salt is formed by reacting the free base form of compound A with a counter acid (e.g., p-toluenesulfonic acid) in a solvent or mixtures thereof selected from methanol, dimethylsulfoxide, acetone, acetonitrile, ethyl acetate, toluene, 2-butanone, benzonitrile, cyclohexane, tetrahydrofuran, and diisopropyl ether, and optionally further containing water or hexane.

[0042] 1.21 Any of the preceding forms of salt 1, wherein the salt is a solvate, for example, a solvate selected from a methanol solvate, a dimethylsulfoxide solvate, an acetone solvate, an acetonitrile solvate, an ethyl acetate solvate, a toluene solvate, or a 2-butanone solvate.

[0043] 1.22 Any of the preceding forms of salt 1, wherein the salt is not a solvate.

[0044] 1.23 Any of the above forms of salt 1, wherein the salt is a hydrate.

[0045] 1.24 Any of the preceding forms of salt 1, wherein the salt is not a hydrate.

[0046] 1.25 Any of the above forms of Salt 1, wherein the salt is a toluenesulfonic acid addition salt prepared (e.g., crystallized) from an acetone, ethyl acetate, toluene, or 2-butanone solvent.

[0047] 1.26 Any of the above forms of salt 1, wherein the salt is a toluenesulfonate salt prepared (e.g., crystallized) from acetone or 2-butanone solvent.

[0048] 1.27 Any of the above forms of Salt 1, wherein the salt is a toluenesulfonate salt, and the salt may have been prepared in (e.g., crystallized from) 2-butanone solvent, and the salt has a DSC / TGA thermogram showing one endothermic event at about 40-100° C. (e.g., about 67° C.), a second endothermic event at about 120-180° C. (e.g., about 164° C.), and one exothermic event at about 200-280° C. (e.g., about 256° C.), e.g., the first endothermic event is a desolvation event, and / or the second endothermic event is melting of the salt, and / or the exothermic event is decomposition.

[0049] 1.28 Any of the foregoing forms of Salt 1, wherein the salt is a toluenesulfonate salt, and the salt may have been prepared in (e.g., crystallized from) an acetone solvent, and wherein the salt has a DSC / TGA thermogram showing one endothermic event at about 40-100° C. (e.g., about 56° C.), a second endothermic event at about 120-190° C. (e.g., about 180° C.), a third endothermic event at about 200-220° C. (e.g., about 216° C.), and one exothermic event at about 230-290° C. (e.g., about 269° C.), e.g., the first endothermic event is a desolvation event, and / or the second endothermic event is melting of the salt, and / or the exothermic event is decomposition.

[0050] 1.29 The salt may be a toluenesulfonate salt, and the salt may be prepared in (e.g., crystallized from) 2-butanone solvent, and the salt has a DSC / TGA thermogram that shows one endothermic event at about 84° C. and a second exothermic event at about 180° C., e.g., the DSC / TGA thermogram shows an endothermic event at about T オンセット = 49℃, T ピーク = 84 °C and ΔE = -13 J / g, and the first endothermic event at about T オンセット = 166°C, T ピーク = 180 ° C and a second endothermic event at ΔE = -47 J / g , e.g. , the first endothermic event is desolvation and the second endothermic event is melting .

[0051] 1.30 Any of the above forms of Salt 1, wherein the salt is a toluenesulfonate salt, and the salt may have been prepared in (e.g., crystallized from) 2-butanone or acetone solvent, and the salt has a DSC / TGA thermogram as shown in Figure 2 or Figure 3.

[0052] 1.31 Any of the above forms of Salt 1, wherein the salt is a toluenesulfonate salt, and the salt may have been prepared in (e.g., crystallized from) 2-butanone or acetone solvent, and the salt has a crystalline structure characterized by an X-ray powder diffraction pattern corresponding to the d-spacings and / or angle (2θ) values ​​in the following table, e.g., the pattern includes at least 5 of said values, or at least 6, or at least 7, or at least 8 of said values, taking into account, e.g., potential variations due to sample purity and instrumental variations, e.g., 2θ shifts due to variations in X-ray wavelength, e.g., the X-ray powder diffraction pattern is generated using an X-ray diffractometer equipped with a copper anode and nickel filter, and includes, e.g., at least, those peaks having a relative intensity of at least 0.4, at least 0.5, or at least 0.6, or includes 5, 6, 7, 9, 10 and 12 peaks: [Table 1]

[0053] 1.32 Any of the above forms of Salt 1, wherein the salt is a toluenesulfonate salt, and the salt may have been prepared in (e.g., crystallized from) 2-butanone or acetone solvent, and the salt has a crystalline structure characterized by an X-ray powder diffraction pattern corresponding to FIG. 1, taking into account, for example, sample purity and potential variations due to instrumental variations, e.g., 2θ shift due to variations in X-ray wavelength, e.g., an X-ray powder diffraction pattern corresponding to FIG. 1 generated, for example, using an X-ray diffractometer equipped with a copper anode and nickel filter.

[0054] 1.33 The salt may be a toluenesulfonate salt, and the salt may be prepared in (e.g., crystallized from) 2-butanone or acetone solvent, and the salt may have a pH of about 5.9, 8.6, 11.4, 13.6, 14.9, 17.0, 19.4, 20.0, 20.9, 22.6, 23.8, 24.6, 25.3, 25.6, 25.9, 27.5, 28.0, 29.0, 30.0, 31.0, 32.0, 33.0, 34.0, 35.0, 36.0, 37.0, 38.0, 39.0, 40.0, 41.0, 42.0, 43.0, 44.0, 45.0, 46.0, 47.0, 48.0, 49.0, 50.0, 51.0, 52.0, 53.0, 54.0, 55.0, 56.0, 57.0, 58.0, 59.0, 60.0, 61.0, 62.0, 63.0, 64.0, 65.0, 66.0, 67.0, 68.0, 69.0, 70.0, 71.0, 72.0, 73.0, 74.0, 75.0, 76.0, 77.0, 78.0, 79.0, 80.0, 81.0, 82.0, 83.0, 84.0, 85.0, 86.0, 87.0, Any of the foregoing forms of Salt 1 have a crystalline structure characterized by an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8 peaks having angle (2θ) values ​​selected from the group consisting of 9.9, 32.5, 33.6, 36.6, 36.6 and 36.6, e.g., the X-ray powder diffraction pattern is generated using an X-ray diffractometer equipped with a copper anode and a nickel filter.

[0055] 1.34 The salt may be a toluenesulfonate salt, and the salt may be prepared in (e.g., crystallized from) a 2-butanone or acetone solvent, and the salt may have a pH of about 5.88, 8.63, 11.44, 13.55, 14.93, 16.98, 19.37, 19.96, 20.94, 22.59, 23.81, 24.57, 25.34, 25.61, 25.94, 27.53, 28.04, 29.04, 30.04, 31.04, 32.04, 33.04, 34.04, 35.04, 36.04, 37.04, 38.04, 39.04, 40.04, 41.04, 42.04, 43.04, 44.04, 45.04, 46.04, 47.04, 48.04, 49.04, 50.04, 51.04, 52.04, 53.04, 54.04, 55.04, 56.04, 57.04, 58.04, 59.04, 60.04, 61.04, 62.04, 63.04, 64.04, 65.04, 66.04, 67.04, 68.04, 69.04, 70.04, 71.04, 72.04, 73.04, 74.04, 75.04, 76.04, Any of the foregoing forms of Salt 1 have a crystalline structure characterized by an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8 peaks having angle (2θ) values ​​selected from the group consisting of 8.97, 29.94, 32.53, 33.61, 36.55, 36.59 and 36.62, e.g., the X-ray powder diffraction pattern is generated using an X-ray diffractometer equipped with a copper anode and a nickel filter.

[0056] 1.35 The salt may be a toluenesulfonate salt, and the salt may be prepared in (e.g., crystallized from) 2-butanone or acetone solvent, and the salt may have a pH of about 15.03, 10.24, 7.73, 6.53, 5.93, 5.22, 4.58, 4.45, 4.24, 3.93, 3.74, 3.62, 3.51, 3.48, 3.43, 3.24, 3.18, 3. 08, 2.98, 2.75, 2.66, 2.46, 2.454 and 2.452, wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer equipped with a copper anode and a nickel filter.

[0057] 1.36 Any of the foregoing forms of Salt 1, wherein the salt is a toluenesulfonate salt, and the salt may have been prepared in (e.g., crystallized from) 2-butanone or acetone solvent, and the salt has a crystalline structure characterized by an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8 peaks having d-spacing values ​​selected from the group consisting of about 15.0, 10.2, 7.7, 6.5, 5.9, 5.2, 4.6, 4.5, 4.2, 3.9, 3.7, 3.6, 3.5, 3.5, 3.4, 3.2, 3.2, 3.1, 3.0, 2.8, 2.7, 2.5, 2.5, and 2.5, taking into account potential variations due to sample purity and instrumental variations, and wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer equipped with a copper anode and a nickel filter.

[0058] 1.37 Any of the above forms of Salt 1, wherein the salt is a toluenesulfonate salt, and the salt may have been prepared in (e.g., crystallized from) 2-butanone or acetone solvent, and the salt has an X-ray powder diffraction pattern as shown in or substantially as shown in FIG. 1.

[0059] 1.38 Any of the above forms of Salt 1, wherein the salt is a toluenesulfonate salt, which may have been prepared in 2-butanone or acetone solvent, and wherein the salt has a crystalline structure characterized by an X-ray powder diffraction pattern corresponding to the d-spacings and / or angle (2θ) values ​​in the following table, e.g., the pattern comprises at least 5 of said values, or at least 6, or at least 7, or at least 8 of said values, taking into account, e.g., potential variations due to sample purity and instrumental variations, e.g., 2θ shifts due to variations in X-ray wavelength, e.g., the X-ray powder diffraction pattern is generated using an X-ray diffractometer equipped with a copper anode and a nickel filter, and comprises, e.g., at least, those peaks having a relative intensity of at least 0.4, at least 0.5, or at least 0.6, or comprises 1, 2, 3, 4, 5, 6, 8, 10, 11, 12, 13, 21, 23, and 27 peaks: [Table 2]

[0060] 1.39 Any of the above forms of Salt 1, wherein the salt is a toluenesulfonate salt, and the salt may have been prepared in (e.g., crystallized from) 2-butanone or acetone solvent, and wherein the salt has a crystal structure characterized by an X-ray powder diffraction pattern corresponding to FIG. 4, e.g., an X-ray powder diffraction pattern corresponding to FIG. 1 generated, e.g., using an X-ray diffractometer equipped with a copper anode and nickel filter, taking into account, e.g., sample purity and potential variations due to instrumental variations, e.g., 2θ shift due to variations in X-ray wavelength.

[0061] 1.40 The salt may be a toluenesulfonate salt, and the salt may be prepared in (e.g., crystallized from) 2-butanone or acetone solvent, and the salt may have a pH of about 2.9, 5.7, 8.5, 11.3, 13.4, 14.8, 16.6, 17.0, 18.4, 18.7, 19.2, 19.5, 19.8, 20.2, 20.8, 22.2, 22.5, 22.7, 23.3, 23.7, 24.5, 25.1, 25.6, 25.9, 26.9, 27.4, 28.6, 29.7, 30.2, 31.0, 32.0, 33.0, 34.0, 35.0, 36.0, 37.0, 38.0, 39.0, 40.0, 41.0, 42.0, 43.0, 44.0, 45.0, 46.0, 47.0, 48.0, 49.0, 50.0, 51.0, 52.0, 53.0, 54.0, 55.0, 56.0, 57.0, 58.0, 59.0, 60.0, 61.0, 62.0, 63.0, 64.0, 65.0, 66.0, 67.0, 68.0, 69.0, 70.0, 71.0, 72.0, 73.0, 74.0, 75.0, 76.0, 77.0, , 27.5, 28.0, 28.4, 28.8, 29.9, 31.4, 32.5, 33.7, 34.2, 36.5, 37.3, 37.9 and 39.3, e.g., wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer equipped with a copper anode and a nickel filter.

[0062] 1.41 The salt may be a toluenesulfonate salt, and the salt may be prepared in (e.g., crystallized from) 2-butanone or acetone solvent, and the salt may have a pH of about 2.89, 5.66, 8.46, 11.29, 13.41, 14.82, 16.62, 16.96, 18.43, 18.68, 19.19, 19.46, 19.83, 20.23, 20.83, 22.16, 22.51, 22.68, 23.31, 23.67, 24.51, 25.08, 25.55, 25.87, 26.87, taking into account potential variations due to sample purity and instrument variation. , 27.41, 27.47, 28.00, 28.43, 28.83, 29.92, 31.35, 32.50, 33.74, 34.22, 36.51, 37.34, 37.90 and 39.29, e.g., wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer equipped with a copper anode and a nickel filter.

[0063] 1.42 The salt may be a toluenesulfonate salt, and the salt may be prepared in (e.g., crystallized from) 2-butanone or acetone solvent, and the salt may have a pH of about 30.59, 15.63, 10.45, 7.84, 6.60, 5.98, 5.33, 5.23, 4.81, 4.75, 4.63, 4.56, 4.48, 4.39, 4.26, 4.01, 3.95, 3.92, 3.82, 3.76, 3.63, 3.55, 3.49, 3.44, 3.32, 3. Any of the foregoing forms of Salt 1 have a crystalline structure characterized by an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8 peaks having d-spacing values ​​selected from the group consisting of 0.252, 3.247, 3.19, 3.14, 3.10, 3.05, 2.99, 2.85, 2.76, 2.66, 2.62, 2.46, 2.41, 2.37 and 2.29, wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer equipped with a copper anode and a nickel filter.

[0064] 1.43 The salt may be a toluenesulfonate salt, and the salt may be prepared in (e.g., crystallized from) 2-butanone or acetone solvent, and the salt may have a pH of about 30.6, 15.6, 10.5, 7.8, 6.6, 6.0, 5.3, 5.2, 4.8, 4.8, 4.6, 4.6, 4.5, 4.4, 4.3, 4.0, 4.0, 3.9, 3.8, 3.8, 3.6, 3.6, 3.5, 3.4, 3.3, 3.3, 3. Any of the above forms of Salt 1 has a crystalline structure characterized by an X-ray powder diffraction pattern having at least five, or at least six, or at least seven, or at least eight peaks having d-spacing values ​​selected from the group consisting of 0.3, 3.2, 3.1, 3.1, 3.1, 3.0, 2.9, 2.8, 2.7, 2.6, 2.5, 2.4, 2.4 and 2.3, wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer equipped with a copper anode and a nickel filter.

[0065] 1.44 Any of the above forms of Salt 1, wherein the salt is a toluenesulfonate salt, and the salt may have been prepared in (e.g., crystallized from) a 2-butanone or acetone solvent, and the salt has an X-ray powder diffraction pattern as shown in or substantially as shown in FIG. 4.

[0066] 1.45 Any of the above forms of Salt 1 (e.g., any of Salts 1.38-1.44), wherein the salt is a toluenesulfonate salt, the salt may have been prepared in (e.g., crystallized from) 2-butanone solvent, the salt may have a DSC thermogram showing one endothermic event at about 186-190°C (e.g., peak 188°C), a sharp exothermic event at about 189-202°C (e.g., peak 189°C), a second endothermic event at about 225-230°C (e.g., peak 226°C), and a second exothermic event at about 260-310°C (e.g., peak 304°C), e.g., the first endothermic event is a melting event, the first exothermic event is recrystallization, the second endothermic event is a melting event, and the second exothermic event is decomposition, and the salt may have a TG thermogram showing a single mass loss beginning at about 250°C.

[0067] 1.46 Any of the above forms of Salt 1, wherein the salt is a toluenesulfonate salt, and the salt may have been prepared in (e.g., crystallized from) 2-butanone or acetone solvent, and the salt has the DSC thermogram shown in FIG. 5 and / or the TGA thermogram shown in FIG. 6.

[0068] 1.47 Any of the above forms of salt 1, wherein the salt is a toluenesulfonate salt and the salt may have been prepared in (e.g., crystallized from) 2-butanone or acetone solvent, and the salt has a melting point of about 163° C.

[0069] 1.48 Any of the above forms of salt 1, wherein the salt is a toluenesulfonate salt and the salt may have been prepared in (e.g., crystallized from) 2-butanone or acetone solvent, and the salt crystals have a monoclinic form.

[0070] 1.49 Any of the foregoing forms of Salt 1, wherein the salt is a toluenesulfonate salt, and the salt may have been prepared in (e.g., crystallized from) 2-butanone or acetone solvent, and the salt has an X-ray powder diffraction pattern having relative angle (2θ) values ​​as provided in any one of embodiments 1.31-1.44 above, wherein the values ​​are shifted by up to ±0.2°, e.g., the values ​​are substantially uniformly shifted by up to ±0.2°.

[0071] 1.50 Any one of salts 1.26 to 1.49, wherein the salt is prepared in acetone solvent.

[0072] 1.51 The salt may be prepared by mixing 1 equivalent of Compound A free base with 0.95-1.25 equivalents of p-toluenesulfonic acid (e.g., p-toluenesulfonic acid monohydrate) in acetone solvent, where the p-toluenesulfonic acid is added to the reaction as a solution in acetone solvent, salt 1.50.

[0073] 1.52 The reaction comprises 0.95 to 1.15 equivalents, or 0.95 to 1.10 equivalents, or 0.95 to 1.05 equivalents, or 0.95 to 1.00 equivalents, or 0.95 to 0.99 equivalents of p-toluenesulfonic acid (e.g., p-toluenesulfonic acid monohydrate), salt 1.51.

[0074] 1.53 Any of salts 1.50 to 1.52, wherein the salt is prepared at a temperature between 0°C and 40°C, e.g., between 0°C and 30°C, or between 0°C and 25°C, or between 0°C and 15°C, or between 5°C and 20°C, or between 5°C and 15°C, or between 10°C and 20°C, or between 10°C and 15°C, or between 5°C and 10°C, or a combination thereof.

[0075] 1.54 Any one of salts 1.50 to 1.53, wherein the salt is isolated by filtration from the reaction mixture, the filtration optionally being carried out at 0°C to 15°C, or 5°C to 15°C, or 0°C to 10°C, or 5°C to 10°C.

[0076] 1.55 After filtration, the salt may be washed with a solvent (e.g., acetone, 2-butanone, methyl tert-butyl ether, or a combination thereof), washed with a cold solvent (e.g., 0°C to 15°C or 5°C to 10°C), or dried at an elevated temperature (e.g., 30 to 100°C, or 40 to 80°C, or 40 to 60°C, or 40 to 50°C), salt 1.54.

[0077] 1.56 Any one of salts 1.26 to 1.55, wherein the salt is white, off-white, pale yellow, light yellow, or gray (e.g., the salt is not purple), and the salt does not have to be purple.

[0078] 1.57 Any of the preceding forms of salt 1, wherein the salt is an oxalate salt prepared from (e.g., crystallized from) an acetone, ethyl acetate, acetonitrile, or 2-butanone solvent.

[0079] 1.58 Any of the previous forms of salt 1, wherein the salt is an oxalate salt prepared from (e.g., crystallized from) acetonitrile or ethyl acetate solvent.

[0080] 1.59 The salt may be an oxalate salt, the salt being prepared from (e.g., crystallized from) an acetonitrile solvent, the salt having a DSC / TGA thermogram showing one endothermic event at about 214° C. and a second endothermic event at about 225° C., e.g., the DSC / TGA thermogram showing a temperature of about T オンセット = 209℃, T ピーク = 214°C and ΔE = -88 J / g, e.g., the first endothermic event is a melt.

[0081] 1.60 The salt may be an oxalate salt, the salt being prepared in (e.g., crystallized from) an ethyl acetate solvent, the salt having a DSC / TGA thermogram showing one endothermic event at about 215° C., a second endothermic event at about 216° C., and one exothermic event at about 225° C., e.g., the DSC / TGA thermogram showing an endothermic event at about T オンセット = 209℃, T ピーク = 215 ° C and ΔE = -89 J / g, and the first endothermic event at about T オンセット = 211℃, T ピーク = 225 ° C and the second endothermic event is ΔE = -28.8 J / g , e.g. , the first endothermic event is desolvation and the second endothermic event is melting .

[0082] 1.61 Any of the above forms of Salt 1, wherein the salt is an oxalate salt, and the salt may have been prepared in (e.g., crystallized from) an acetonitrile or ethyl acetate solvent, and the salt has the DSC / TGA thermogram shown in FIG. 8.

[0083] 1.62 Any of the above forms of Salt 1, wherein the salt is an oxalate salt, and the salt may have been prepared in (e.g., crystallized from) an acetonitrile or ethyl acetate solvent, and the salt has a crystalline structure characterized by an X-ray powder diffraction pattern corresponding to the d-spacings and / or angle (2θ) values ​​in the following table, e.g., the pattern includes at least 5 of said values, or at least 6, or at least 7, or at least 8 of said values, taking into account, e.g., potential variations due to sample purity and instrumental variations, e.g., 2θ shifts due to variations in X-ray wavelength, e.g., the X-ray powder diffraction pattern is generated using an X-ray diffractometer equipped with a copper anode and a nickel filter, and includes, e.g., at least, those peaks having a relative intensity of at least 0.4, at least 0.5, or at least 0.6, or includes 5, 6, 7, 9, 10 and 12 peaks: [Table 3]

[0084] 1.63 Any of the above forms of Salt 1, wherein the salt is an oxalate salt, and the salt may have been prepared in (e.g., crystallized from) an acetonitrile or ethyl acetate solvent, and wherein the salt has a crystal structure characterized by an X-ray powder diffraction pattern corresponding to FIG. 7, e.g., an X-ray powder diffraction pattern corresponding to FIG. 1 generated, e.g., using an X-ray diffractometer equipped with a copper anode and nickel filter, taking into account, e.g., sample purity and potential variations due to instrumental variations, e.g., 2θ shifts due to variations in X-ray wavelength.

[0085] 1.64 Any of the foregoing forms of Salt 1, wherein the salt is an oxalate salt, and the salt may have been prepared in (e.g., crystallized from) an acetonitrile or ethyl acetate solvent, and the salt has a crystalline structure characterized by an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8 peaks having angle (2θ) values ​​selected from the group consisting of about 12.1, 13.5, 14.1, 15.7, 17.2, 17.7, 18.2, 19.8, 21.0, 22.1, 23.2, 23.3, 24.1, 26.2, 28.1, and 29.1, taking into account potential variations due to sample purity and instrumental variations, e.g., the X-ray powder diffraction pattern is generated using an X-ray diffractometer equipped with a copper anode and a nickel filter.

[0086] 1.65 Any of the foregoing forms of Salt 1, wherein the salt is an oxalate salt, and the salt may have been prepared in (e.g., crystallized from) an acetonitrile or ethyl acetate solvent, and the salt has a crystalline structure characterized by an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8 peaks having angle (2θ) values ​​selected from the group consisting of about 12.05, 13.52, 14.10, 15.70, 17.20, 17.71, 18.22, 19.83, 20.96, 22.05, 23.20, 23.32, 24.10, 26.15, 28.07, and 29.07, taking into account potential variations due to sample purity and instrumental variations, e.g., the X-ray powder diffraction pattern is generated using an X-ray diffractometer equipped with a copper anode and a nickel filter.

[0087] 1.66 Any of the foregoing forms of Salt 1, wherein the salt is an oxalate salt, and the salt may have been prepared in (e.g., crystallized from) an acetonitrile or ethyl acetate solvent, and the salt has a crystalline structure characterized by an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8 peaks having d-spacing values ​​selected from the group consisting of about 7.34, 6.55, 6.28, 5.64, 5.15, 5.00, 4.86, 4.47, 4.24, 4.03, 3.83, 3.81, 3.69, 3.40, 3.18, and 3.07, taking into account potential variations due to sample purity and instrumental variations, and wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer equipped with a copper anode and a nickel filter.

[0088] 1.67 Any of the foregoing forms of Salt 1, wherein the salt is an oxalate salt, and the salt may have been prepared in (e.g., crystallized from) an acetonitrile or ethyl acetate solvent, and the salt has a crystalline structure characterized by an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8 peaks having d-spacing values ​​selected from the group consisting of about 7.3, 6.6, 6.3, 5.6, 5.2, 5.0, 4.9, 4.5, 4.2, 4.0, 3.8, 3.8, 3.7, 3.4, 3.2, and 3.1, taking into account potential variations due to sample purity and instrumental variations, and wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer equipped with a copper anode and a nickel filter.

[0089] 1.68 Any of the above forms of Salt 1, wherein the salt is an oxalate salt, and the salt may have been prepared in (e.g., crystallized from) an acetonitrile or ethyl acetate solvent, and the salt has an X-ray powder diffraction pattern as shown in or substantially as shown in FIG. 7.

[0090] 1.69 Any of the foregoing forms of Salt 1, wherein the salt is an oxalate salt, and the salt may have been prepared in (e.g., crystallized from) an acetonitrile or ethyl acetate solvent, and the salt has an X-ray powder diffraction pattern having relative angle (2θ) values ​​as provided in any one of embodiments 1.62-1.65 above, wherein the values ​​are shifted by up to ±0.2°, e.g., the values ​​are substantially uniformly shifted by up to ±0.2°.

[0091] 1.70 Any of the above forms of Salt 1 (e.g., the toluenesulfonate salt, where the salt may have been prepared in (e.g., crystallized from) 2-butanone or acetone solvent) containing less than 5000 ppm total residual solvent (e.g., acetone or 2-butanone), e.g., less than 4000 ppm, or less than 3000 ppm, or less than 2000 ppm, or less than 1000 ppm, or less than 750 ppm, or less than 500 ppm, or less than 250 ppm, or less than 150 ppm, or less than 100 ppm, or less than 50 ppm total residual solvent.

[0092] 1.71 Any of the above forms of salt 1 (e.g., the toluenesulfonate salt, where the salt may have been prepared in (e.g., crystallized from) 2-butanone or acetone solvent) containing less than 100 ppm, e.g., less than 75 ppm, or less than 50 ppm, or less than 25 ppm, or less than 20 ppm, or less than 15 ppm, or less than 10 ppm, of 1-(3-chloropropoxy)-4-fluorobenzene.

[0093] 1.72 Any of the foregoing forms of salt 1 (e.g., the toluenesulfonate salt, where the salt may have been prepared in (e.g., crystallized from) 2-butanone or acetone solvent) wherein the salt contains less than 5% water by weight, e.g., less than 4% by weight, or less than 3% by weight, or less than 2% by weight, or less than 1% by weight, or less than 0.9% by weight, or less than 0.8% by weight, or less than 0.7% by weight, or less than 0.6% by weight, or less than 0.5% by weight.

[0094] 1.73 Any of the foregoing forms of Salt 1 (e.g., a toluenesulfonate salt, where the salt may have been prepared in (e.g., crystallized from) 2-butanone or acetone solvent) wherein the salt comprises less than 100 ppm of p-toluenesulfonic acid alkyl esters (e.g., methyl ester, ethyl ester and / or isopropyl ester), e.g., less than 75 ppm, or less than 50 ppm, or less than 40 ppm, or less than 30 ppm, or less than 20 ppm of p-toluenesulfonic acid alkyl esters.

[0095] 1.74 Any of the foregoing forms of Salt 1 (e.g., a toluenesulfonate salt, where the salt may have been prepared in (e.g., crystallized from) 2-butanone or acetone solvent) wherein the salt comprises less than 50 ppm of any p-toluenesulfonic acid alkyl ester (e.g., methyl ester, ethyl ester and / or isopropyl ester), e.g., less than 40 ppm, or less than 30 ppm, or less than 25 ppm, or less than 20 ppm, or less than 15 ppm, or less than 10 ppm of any p-toluenesulfonic acid alkyl ester, e.g., less than 20 ppm of any p-toluenesulfonic acid alkyl ester.

[0096] 1.75 Any of the above forms of Salt 1 (e.g., the toluenesulfonate salt, where the salt may have been prepared in (e.g., crystallized from) 2-butanone or acetone solvent) wherein the salt has a particle size of less than 50 microns, e.g., the salt particles have a D90 of less than 50 μm, or less than 40 μm, or less than 30 μm, or less than 20 μm, or less than 10 μm.

[0097] 1.76 Any of the preceding forms of salt 1, wherein the salt exhibits any combination of the characteristics described in 1.1 to 1.75.

[0098] In a second embodiment, the present invention provides a solid co-crystal form of (6bR,10aS)-8-(3-(4-fluorophenoxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (Compound A) (Co-crystal 2).

[0099] In further embodiments, the present disclosure provides:

[0100] 2.1 Co-crystal 2, wherein the co-crystal is at least 90% pure, e.g., at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% pure, e.g., as shown by LCMS.

[0101] 2.2 Cocrystal 2 or 2.1, wherein the cocrystal contains less than 10% by weight, e.g., less than 8% by weight, or less than 6% by weight, or less than 5% by weight, or less than 4% by weight, or less than 3% by weight, or less than 2% by weight, or less than 1% by weight, or less than 0.5% by weight, or less than 0.1% by weight of Compound A in free base form.

[0102] 2.3 Cocrystal 2, or any of 2.1-2.2, wherein the cocrystal contains less than 10 wt.%, e.g., less than 8 wt.%, or less than 6 wt.%, or less than 5 wt.%, or less than 4 wt.%, or less than 3 wt.%, or less than 2 wt.%, or less than 1 wt.%, or less than 0.5 wt.%, or less than 0.1 wt.% of compound A in any other cocrystal form.

[0103] 2.4 Co-crystal 2, or any of 2.1-2.3, wherein the salt contains less than 10 wt.%, e.g., less than 8 wt.%, or less than 6 wt.%, or less than 5 wt.%, or less than 4 wt.%, or less than 3 wt.%, or less than 2 wt.%, or less than 1 wt.%, or less than 0.5 wt.%, or less than 0.1 wt.% of any free crystal coformer (e.g., alanine, phenylalanine, or other amino acids).

[0104] 2.5 Cocrystal 2, or any of 2.1-2.4, wherein the cocrystal contains less than 10 wt.%, e.g., less than 8 wt.%, or less than 6 wt.%, or less than 5 wt.%, or less than 4 wt.%, or less than 3 wt.%, or less than 2 wt.%, or less than 1 wt.%, or less than 0.5 wt.%, or less than 0.1 wt.% of any free solvent (e.g., other than the solvent contained in the solvated cocrystal form).

[0105] 2.6 Cocrystal 2, or any of 2.1-2.5, wherein the cocrystal contains less than 10 wt%, e.g., less than 8 wt%, or less than 6 wt%, or less than 5 wt%, or less than 4 wt%, or less than 3 wt%, or less than 2 wt%, or less than 1 wt%, or less than 0.5 wt%, or less than 0.1 wt%, of synthetic precursors or by-products from the synthetic method used to prepare the free base form of Compound A.

[0106] 2.7 Cocrystal 2, or any of 2.1-2.6, wherein the cocrystal is in a homogeneous crystalline form, e.g., free or substantially free of other crystalline forms or polymorphs or amorphous forms of Compound A, e.g., free or substantially free of any other crystalline forms or polymorphs or amorphous forms, e.g., containing less than 10% by weight, preferably less than about 5% by weight, more preferably less than about 2% by weight, even more preferably less than about 1% by weight, even more preferably less than about 0.1% by weight, and most preferably less than about 0.01% by weight.

[0107] 2.8 Cocrystal 2, or any of 2.1-2.7, wherein the cocrystal is with an amino acid (e.g., a natural alpha amino acid).

[0108] 2.9 Co-crystal 2.8, wherein the amino acids are selected from alanine, asparagine, cysteine, methionine, phenylalanine, proline, serine, glutamine, glycine, histidine, lysine, threonine, tyrosine, and valine.

[0109] 2.10 Co-crystal 2.8, wherein the amino acids are selected from alanine, cysteine, methionine, phenylalanine, serine, glycine, histidine and valine.

[0110] 2.11 The amino acid is alanine, co-crystal 2.8.

[0111] 2.12 The amino acid is phenylalanine, cocrystal 2.8.

[0112] 2.13 Cocrystal 2, or any of 2.1-2.12, wherein the cocrystal comprises Compound A free base and a coformer (e.g., alanine or phenylalanine) in a molar ratio of 1:2, 1:1, 2:1, 3:1, or 4:1.

[0113] 2.14 Co-crystal 2, or any of 2.1-2.13, wherein the co-crystal is formed by reacting the free base form of compound A with a co-former (e.g., alanine or phenylalanine) in a solvent selected from methanol, dimethylsulfoxide, acetone, or acetonitrile, e.g., in acetone or acetonitrile.

[0114] In another aspect, the present invention provides a method for preparing a solid crystalline salt form of (6bR,10aS)-8-(3-(4-fluorophenoxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (Compound A) (e.g., Salt 1), comprising: (a) reacting (6bR,10aS)-8-(3-(4-fluorophenoxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (Compound A) free base with an acid selected from hydrochloric acid, p-toluenesulfonic acid, tartaric acid, malic acid, fumaric acid, glutamic acid, oxalic acid, benzenesulfonic acid and ascorbic acid, for example together with an organic solvent (e.g., containing 2-butanone or acetone); and (b) recovering the salt thus formed, e.g., recovering salt 1, or any of salts 1.1-1.76. The present invention provides a production method (production method 1), which includes the steps of:

[0115] In a further embodiment of Production Method 1, the present disclosure provides:

[0116] 1.1 Preparation method 1, wherein the acid is selected from p-toluenesulfonic acid, tartaric acid, malic acid, fumaric acid, glutamic acid, oxalic acid, benzenesulfonic acid and ascorbic acid.

[0117] 1.2 Process 1.1, wherein the acid is selected from p-toluenesulfonic acid and oxalic acid.

[0118] 1.3 Preparation method 1.2, wherein the acid is oxalic acid and the salt is any one of salts 1.57 to 1.69.

[0119] 1.4 Preparation method 1.2, wherein the acid is p-toluenesulfonic acid and the salt is any one of salts 1.25 to 1.56 or 1.70 to 1.76.

[0120] 1.5 Preparation method 1, or any of 1.1 to 1.4, wherein the solvent in step (a) is selected from methanol, dimethyl sulfoxide, acetone, acetonitrile, ethyl acetate, toluene, 2-butanone, benzonitrile, cyclohexane, tetrahydrofuran and diisopropyl ether or a mixture thereof, and may further contain water or hexane.

[0121] 1.6 Process 1.5, wherein the solvent is selected from acetone, acetonitrile, ethyl acetate, toluene and 2-butanone or a mixture thereof.

[0122] 1.7 Process 1.6, wherein the solvent is selected from acetone and 2-butanone.

[0123] 1.8. Process 1.7, wherein the solvent is acetone, e.g., the solvent consists of acetone.

[0124] 1.9 Any of processes 1 or 1.1 to 1.8, wherein the compound of formula A and the acid are mixed in step (a) in a molar ratio of about 1:0.9 to 1:5, for example, 1:0.9 to 1:3, or 1:0.9 to 1:1.5, or 1:0.9 to 1:1.2, or 1:0.9 to 1:1.1, or in a molar ratio of about 1:1.

[0125] 1.10 Any of Preparations 1 or 1.1-1.9, wherein in step (a) a solution of the acid in the solvent is added to a solution of Compound A free base in the solvent.

[0126] 1.11 Process 1.10, wherein the concentration of Compound A free base in the solvent (before addition of the acid) is about 0.1-0.3 g / mL, e.g., 0.1-0.15 g / mL, or about 0.1 or 0.11 g / mL.

[0127] 1.12 Process 1.10 or 1.11, wherein the concentration of the acid in the solvent (before adding the acid to the free base solution) is about 1 M to 5 M, e.g., 2 M to 3 M, or about 2.5 M, e.g., the acid is p-toluenesulfonic acid monohydrate and the concentration is about 0.3 to 1 g / mL, e.g., 0.37 to 0.55 g / mL, or about 0.45 g / mL.

[0128] 1.13 Any of Processes 1 or 1.1-1.12, wherein step (a) comprises 1 equivalent of the free base form of Compound A, the solvent, and 0.95-1.15 equivalents of the acid (e.g., p-toluenesulfonic acid monohydrate), or 0.95-1.10 equivalents, or 0.95-1.05 equivalents, or 0.95-1.00 equivalents, or 0.95-0.99 equivalents.

[0129] 1.14 Preparation method 1.13, wherein the net concentration of Compound A after all solvent addition is about 0.1-0.3 g / mL, for example, 0.1-0.15 g / mL, or about 0.1 g / mL.

[0130] 1.15 Any of Production Methods 1, or 1.1-1.14, wherein step (a) occurs at a temperature of 0°C to 40°C, e.g., 0°C to 30°C, or 0°C to 25°C, or 0°C to 15°C, or 5°C to 20°C, or 5°C to 15°C, or 10°C to 20°C, or 10°C to 15°C, or 5°C to 10°C, or a combination thereof.

[0131] 1.16. Preparation method 1.14, wherein the Compound A free base, the acid and the solvent are mixed at a temperature of 10° C. to 20° C., or 10° C. to 15° C., and after the mixing is completed, the reaction is cooled to a temperature of 5° C. to 15° C., or 5° C. to 10° C., or about 5° C.

[0132] 1.17 Any of process 1 or 1.1-1.16, wherein step (a) occurs for 12 to 24 hours, e.g., 14 to 20 hours or 14 to 16 hours.

[0133] 1.18. Any of Preparation Methods 1, or 1.1-1.17, wherein step (b) comprises isolating the precipitated salt product by filtration, followed by washing with a solvent (e.g., acetone, 2-butanone, methyl tert-butyl ether, or a combination thereof).

[0134] 1.19. Process 1.18, wherein the filtration and washing are carried out at 0°C to 15°C, or 5°C to 15°C, or 0°C to 10°C, or 5°C to 10°C.

[0135] 1.20. Process 1.18 or 1.19, wherein the salt product is washed with cold solvent (e.g., 0° C. to 15° C. or 5° C. to 10° C.).

[0136] 1.21 Any of Preparations 1.18 to 1.20, wherein the washing solvent is acetone.

[0137] 1.22 Any of Production Methods 1.18 to 1.21, wherein step (b) further comprises drying the salt product at elevated temperature (e.g., 30 to 100°C, or 40 to 80°C, or 40 to 60°C, or 40 to 50°C).

[0138] 1.23 Any of Preparation Methods 1, or 1.1-1.22, wherein the preparation method provides a salt containing less than 5000 ppm total residual solvents (e.g., any one or more of acetone, methanol, acetonitrile, methyl tert-butyl ether, ethyl acetate, heptane, toluene, dimethylacetamide, diisopropylamine, and dimethylsulfoxide), e.g., less than 4000 ppm, or less than 3000 ppm, or less than 2000 ppm, or less than 1000 ppm, or less than 750 ppm, or less than 500 ppm, or less than 250 ppm, or less than 150 ppm, or less than 100 ppm, or less than 50 ppm.

[0139] 1.24 The method provides a salt containing less than 5000 ppm of each residual solvent (e.g., any one or more of acetone, methanol, acetonitrile, methyl tert-butyl ether, ethyl acetate, heptane, toluene, dimethylacetamide, diisopropylamine, and dimethyl sulfoxide), for example, less than 4000 ppm, or less than 3000 ppm, or less than 2000 ppm, or less than 1000 ppm, or less than 750 ppm, or less than 500 ppm, or less than 250 ppm, or less than 150 ppm, or less than 100 ppm, or less than 50 ppm of each residual solvent, method 1, or any of 1.1 to 1.23.

[0140] 1.25 Any of Processes 1, or 1.1-1.24, wherein the process provides a salt containing less than 100 ppm 1-(3-chloropropoxy)-4-fluorobenzene, e.g., less than 75 ppm, or less than 50 ppm, or less than 25 ppm, or less than 20 ppm, or less than 15 ppm, or less than 10 ppm.

[0141] 1.26 Any of Production Methods 1, or 1.1-1.25, wherein the production method provides a salt containing less than 5% water by weight, for example, less than 4% by weight, or less than 3% by weight, or less than 2% by weight, or less than 1% by weight, or less than 0.9% by weight, or less than 0.8% by weight, or less than 0.7% by weight, or less than 0.6% by weight, or less than 0.5% by weight.

[0142] 1.27 Any of Production Methods 1, or 1.1-1.26, wherein the production method provides salts containing less than 250 ppm total heavy metals (e.g., arsenic, cadmium, cobalt, lead, nickel, mercury, vanadium, lithium, antimony and / or copper), e.g., less than 150 ppm, or less than 100 ppm, or less than 50 ppm, or less than 25 ppm, or less than 15 ppm, or less than 10 ppm.

[0143] 1.28 Any of Production Methods 1, or 1.1-1.27, wherein the production method provides salts containing less than 50 ppm of any individual heavy metal (e.g., arsenic, cadmium, cobalt, lead, nickel, mercury, vanadium, lithium, antimony and / or copper), e.g., less than 40 ppm, or less than 30 ppm, or less than 25 ppm, or less than 20 ppm, or less than 15 ppm, or less than 10 ppm, or less than 5 ppm, or less than 1 ppm.

[0144] 1.29. Process 1.27 or 1.28, wherein the process provides salts containing less than 50 ppm copper, e.g., less than 40 ppm, or less than 30 ppm, or less than 25 ppm, or less than 20 ppm, or less than 15 ppm, or less than 10 ppm, or less than 5 ppm, or less than 1 ppm.

[0145] 1.30 Any of Processes 1, or 1.1-1.29, wherein the process provides a salt having a particle size of less than 50 microns, e.g., the salt particles have a D90 of less than 50 μm, or less than 40 μm, or less than 30 μm, or less than 20 μm, or less than 10 μm.

[0146] 1.31 Preparation 1, or any of 1.1-1.30, wherein the preparation provides a compound A p-toluenesulfonate salt, e.g., a monotosylate salt.

[0147] 1.32 Preparation 1.31, in which the salt is formed as a white, off-white, light yellow, pale yellow or gray solid (e.g., the salt is not purple).

[0148] 1.33 Process 1.31 or 1.32, wherein the process provides a salt containing less than 100 ppm of p-toluenesulfonic acid alkyl esters (e.g., methyl ester, ethyl ester and / or isopropyl ester), e.g., less than 75 ppm, or less than 50 ppm, or less than 40 ppm, or less than 30 ppm, or less than 20 ppm of p-toluenesulfonic acid alkyl esters.

[0149] 1.34 Process 1.31, 1.32 or 1.33, wherein the process provides a salt containing less than 50 ppm of any p-toluenesulfonic acid alkyl ester (e.g., methyl ester, ethyl ester and / or isopropyl ester), e.g., less than 40 ppm, or less than 30 ppm, or less than 25 ppm, or less than 20 ppm, or less than 15 ppm, or less than 10 ppm of any p-toluenesulfonic acid alkyl ester, e.g., less than 20 ppm of each p-toluenesulfonic acid alkyl ester.

[0150] 1.35 Any of Preparation Methods 1.31 to 1.34, wherein the solvent in step (a) is acetone and the washing solvent in step (b) is acetone.

[0151] 1.36 Any of Preparation Methods 1 or 1.1-1.35, wherein in step (a), the free base form of Compound A is a recrystallized free base form of Compound A, e.g., recrystallized from an acetone or acetone / methanol solution or suspension.

[0152] In another aspect, the present invention provides a method for preparing cocrystal 2, comprising the steps of: (a) reacting (6bR,10aS)-8-(3-(4-fluorophenoxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (Compound A) free base with a crystal co-former, which may be selected from amino acids selected from alanine, asparagine, cysteine, methionine, phenylalanine, proline, serine, glutamine, glycine, histidine, lysine, threonine, tyrosine and valine (e.g., alanine or phenylalanine), for example together with an organic solvent (e.g., selected from methanol, dimethylsulfoxide, acetone or acetonitrile, for example, acetone or acetonitrile); and (b) recovering the cocrystal thus formed, e.g., recovering cocrystal 2, or any of 2.1-2.14. The present invention provides a production method (production method 2) comprising the steps of:

[0153] In another embodiment, the invention provides a pharmaceutical composition comprising as an active ingredient salt 1, or any of salts 1.1-1.76, or cocrystal 2, or any of 2.1-2.14, in combination or association with a pharma- ceutically acceptable diluent or carrier.

[0154] In another embodiment, the invention provides a pharmaceutical composition comprising as an active ingredient salt 1, or any of salts 1.1-1.76, or co-crystal 2, or any of 2.1-2.14, in combination or association with a pharma- ceutically acceptable diluent or carrier, wherein the salt is primarily, or entirely or substantially entirely, in dry crystalline form.

[0155] In certain embodiments, the invention provides a pharmaceutical composition comprising as an active ingredient salt 1, or any of salts 1.1-1.76, or cocrystal 2, or any of 2.1-2.14, in combination or association with a pharma- ceutically acceptable diluent or carrier, wherein the composition is in the form of an injectable depot, e.g., to provide a sustained release of compound A.

[0156] In some embodiments, the pharmaceutical composition is selected from a tablet, a capsule, a caplet, a powder, a wafer, a gel, or a sterile injectable solution. In some embodiments, the pharmaceutical composition is an orally disintegrating tablet. In some embodiments, the pharmaceutical composition is a long-acting injectable composition, e.g., for intramuscular or subcutaneous administration. In some embodiments, the pharmaceutical composition comprises 1-60 mg of Compound A measured by weight of equivalent free base (e.g., for oral ingestible dosage forms, 20-60 mg, or 20-40 mg, or 40-60 mg; e.g., for oral fast dissolving dosage forms, 1-30 mg, or 5-20 mg, or 5-15 mg, or 1-10 mg).

[0157] In another embodiment, the present invention provides a method for the preparation of 5-HT 2Aand diseases or abnormal conditions involving or mediated by receptors, the serotonin transporter (SERT), the dopamine D1 / D2 receptor signaling pathway, and / or the μ-opioid receptor, such as obesity, anxiety, depression (e.g., refractory depression and MDD), psychosis (including psychosis associated with dementia, such as hallucinations or paranoid delusions in advanced Parkinson's disease), schizophrenia, sleep disorders (particularly sleep disorders associated with schizophrenia and other psychiatric and neurological diseases), sexual disorders, migraine, head pain-related conditions, social phobia, agitation in dementia (e.g., agitation in Alzheimer's disease), autism and related autistic disorders, gastrointestinal disorders such as gastrointestinal motility dysfunction, and cognition. or a substance use or abuse disorder (e.g., as these terms are defined in the DSM-V), (possibly in a patient who also suffers from anxiety and / or depression); or an obsessive-compulsive disorder (OCD), obsessive-compulsive personality disorder (OCPD), generalized anxiety disorder (GAD), or a psychiatric disorder (such as chronic kidney disease, chronic bronchitis, or chronic bronchitis), (possibly in a patient who also suffers from depression and / or ... or a combination thereof; or a pain disorder, for example a pain-related condition selected from head pain, idiopathic pain, neuropathic pain, chronic pain (e.g., moderate to moderately severe chronic pain, e.g., in patients requiring 24-hour continuous treatment for another condition), fibromyalgia, toothache, traumatic pain, or chronic fatigue.76, or cocrystal 2, or any of 2.1-2.14 (or wherein the central nervous system disease or disorder is drug addiction (e.g., opiate or opioid addiction (i.e., opioid use disorder), cocaine addiction, amphetamine addiction, and / or alcohol addiction), or withdrawal from drug or alcohol addiction (e.g., opiate addiction, opioid addiction, cocaine addiction, or amphetamine addiction), and the patient also suffers from a comorbid condition such as anxiety, depression, or psychosis, and / or the patient also suffers from opiate overdose or opioid overdose).

[0158] In another embodiment, the present invention provides a method for the preparation of 5-HT 2Aand diseases or abnormal conditions involving or mediated by the opioid receptor, the serotonin transporter (SERT), the dopamine D1 / D2 receptor signaling pathway, and / or the μ-opioid receptor, such as obesity, anxiety, depression (e.g., refractory depression and MDD), psychosis (including psychosis associated with dementia, such as hallucinations or paranoid delusions in advanced Parkinson's disease), schizophrenia, sleep disorders (particularly sleep disorders associated with schizophrenia and other psychiatric and neurological diseases), sexual disorders, migraine, head pain-related conditions, social phobia, agitation in dementia (e.g., agitation in Alzheimer's disease), autism and related autistic disorders, gastrointestinal disorders such as dysfunction of gastrointestinal motility, and dementia, e.g., Alzheimer's dementia or Parkinson's dementia; mood disorder; and drug addiction, such as opiate or opioid addiction, and / or alcohol addiction, or withdrawal from drug or alcohol addiction (e.g., opiate or opioid addiction); or binge eating disorder; or opiate or opioid overdose; or opioid use disorder (OUD), or substance use or abuse disorder (e.g., as these terms are defined in the DSM-V) (possibly in a patient who also suffers from anxiety and / or depression); or obsessive-compulsive disorder (OCD), obsessive-compulsive personality disorder (OCPD), generalized anxiety disorder (GAD), anxiety disorder, social anxiety disorder, panic disorder, agoraphobia, compulsive gambling disorder, compulsive eating disorder, body dysmorphic disorder, hypochondriasis, pathological grooming disorder, kleptomania, pyromania, attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), impulse control disorder, and related disorders, and combinations thereof;or a method for the prevention or treatment of a pain disorder, e.g., a pain-related condition, e.g., a disorder selected from head pain, idiopathic pain, neuropathic pain, chronic pain (e.g., moderate to moderately severe chronic pain, e.g., in patients requiring 24-hour continuous treatment for other diseases), fibromyalgia, dental pain, traumatic pain, or chronic fatigue (or wherein the central nervous system disease or disorder is selected from drug addiction (e.g., opiate or opioid addiction (i.e., opioid use disorder), cocaine addiction, amphetamine addiction, and / or alcohol addiction). and wherein the patient is abstinent from a drug or alcohol addiction (e.g., an opiate addiction, an opioid addiction, a cocaine addiction, or an amphetamine addiction), and the patient also suffers from a co-morbidity such as anxiety, depression, or psychosis, and / or the patient also suffers from an opiate overdose or an opioid overdose, the method comprising administering to a human in need of said prevention or treatment a therapeutically effective amount of salt 1, or any of salts 1.1-1.76, or cocrystal 2, or any of 2.1-2.14;

[0159] In some embodiments of the above methods and uses, the patient is unresponsive to or intolerant of adverse reactions to one or more of: treatment with selective serotonin reuptake inhibitors (SSRIs), such as citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline; treatment with serotonin-norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine, sibutramine, duloxetine, atomoxetine, desvenlafaxine, milnacipran, and levomilnacipran; treatment with antipsychotics, such as clomipramine, risperidone, quetiapine, and olanzapine; treatment with non-narcotic analgesics and / or opiate and opioid drugs (or treatment with other drugs, such as morphine, codeine, thebaine, oripavine, morphine dipropionate, morphine dinicotinate, dihydropyridine ... The use of opiate drugs, such as opiates and opioid drugs including codeine, buprenorphine, etorphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, fentanyl, alpha methylfentanyl, alfentanil, trefantinil, brifentanil, remifentanil, ocfentanil, sufentanil, carfentanil, meperidine, prodine, promedol, propoxyphene, dextropropoxyphene, methadone, diphenoxylate, dezocine, pentazocine, phenazocine, butorphanol, nalbuphine, levorphanol, levomethorphan, tramadol, tapentadol, and anileridine, or combinations thereof, is contraindicated for the patient, e.g., due to past substance abuse or a high likelihood of substance abuse).

[0160] In some embodiments of the above methods and uses, the patient suffers from gastrointestinal and / or pulmonary disorders. Conventional opioid analgesics suffer from two major side effects: gastrointestinal disorders (including nausea, vomiting and constipation) and respiratory depression. 90-95% of patients taking opioids for long-term pain treatment develop severe constipation, necessitating the long-term use of laxatives and / or enemas. Strong opioids such as morphine, oxycodone and hydromorphone cause more severe constipation than other opioids. Respiratory depression is the most significant adverse effect of opioid treatment, with a risk of death occurring especially when patients combine (intentionally or inadvertently) their prescribed opioid analgesics with other legal or illegal respiratory depressants (including alcohol). Thus, patients requiring pain treatment, especially chronic pain treatment, are at particular risk of adverse effects if they suffer from pre-existing gastrointestinal or pulmonary disorders. Unlike conventional opioid analgesics, the compounds of the invention (e.g., salt 1, or any of salts 1.1-1.76, or cocrystal 2, or any of 2.1-2.14) provide analgesic relief without significant adverse gastrointestinal effects and significant respiratory depression. Thus, such compounds would provide improved safety and efficacy for patients in need of pain treatment who have these pre-existing GI and pulmonary disorders. In further embodiments, the compounds of the invention can be combined with conventional opiate agents to provide improved pain control with a dose-sparing effect (and concomitantly reduced risk of adverse effects) over conventional opiate agents.

[0161] In some embodiments of the above methods and uses, the patient suffers from a pre-existing or co-existing gastrointestinal and / or pulmonary disorder, for example the pre-existing or co-existing disorder is selected from the group consisting of irritable bowel syndrome, pelvic floor disorder, diverticulitis, inflammatory bowel disease, colon or colorectal cancer, celiac disease, non-celiac gluten sensitivity, asthma, chronic obstructive pulmonary disease (COPD), dyspnea, pneumonia, congestive heart failure, interstitial lung disease, pneumothorax, bronchitis, pulmonary embolism and traumatic chest injury (e.g., sternal or rib fracture, intercostal muscle contusion). In some embodiments, the central nervous system disorder is a pain disorder, for example a pain-associated condition, for example head pain, idiopathic pain, neuropathic pain, chronic pain (e.g., moderate to moderately severe chronic pain, for example in patients who require 24-hour continuous treatment for other conditions), fibromyalgia, dental pain, traumatic pain or chronic fatigue. In some embodiments, the central nervous system disorder is opioid use disorder, opioid withdrawal, or opioid dependence, and the method provides relief from withdrawal-induced symptoms (e.g., gastrointestinal symptoms such as diarrhea, anxiety, depression, pain, sleep disorders, or a combination thereof).

[0162] In some embodiments of the above methods and uses, the methods further comprise the co-administration, e.g., simultaneous, separate or sequential administration, of another opiate or opioid agent, e.g., the further opiate or opioid agent is morphine, codeine, thebaine, oripavine, morphine dipropionate, morphine dinicotinate, dihydrocodeine, buprenorphine, etorphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, fentanyl, alpha methylfentanyl, alphen In one embodiment, the medicament is selected from the group consisting of methadone, trefantinil, brifentanil, remifentanil, ocfentanil, sufentanil, carfentanil, meperidine, prodine, promedol, propoxyphene, dextropropoxyphene, methadone, diphenoxylate, dezocine, pentazocine, phenazocine, butorphanol, nalbuphine, levorphanol, levomethorphan, tramadol, tapentadol and anileridine, or a combination thereof. Furthermore, in some embodiments of the above methods and uses, the methods further comprise the co-administration of one or more therapeutic agents selected from those described above and further selected from μ opioid, κ opioid, δ opioid, and / or nociceptin / orphanin receptor agonists and partial agonists, or inverse agonists or antagonists, such as opioid receptor antagonists or inverse agonists, such as full opiate antagonists (e.g., selected from naloxone, naltrexone, nalmefene, methadone, nalorphine, levallorphan, samiforphan, nalodein, cyprodime, or nor-binaltorphimine).

[0163] Methods for preparing Compound A and similar compounds, as well as synthetic intermediates useful therefor, are known to those of skill in the art and can be found, for example, in U.S. Pat. Nos. 10,245,260, 10,799,500, 10,961,245, 10,906,906; WO 2020 / 131895 and WO 2020 / 131911, the contents of each of which are incorporated herein by reference in their entirety. EXAMPLES

[0164] The following equipment and methods are used to separate and characterize the exemplified salt forms:

[0165] X-ray powder diffraction (XRPD): X-ray powder diffraction studies were performed using a Bragg-Brentano type Bruker AXS D2 PHASER, instrument #1549. The instrument uses a Cu anode at 30 kV, 10 mA; sample stage standard rotation; monochromatization with a Kβ-filter (0.5% Ni). Slits: fixed divergence slit 1.0 mm (=0.61°), primary axis Soller slit 2.5°, secondary axis Soller slit 2.5°. Detector: linear detector LYNXEYE with receiving slit 5° detection aperture. Standard sample holder (0.1 mm cavity in (510) silicon wafer) has minimal contribution to background signal. Measurement conditions: scan range 5-45° 2θ, sample rotation 5 rpm, 0.5 sec / step, 0.010° / step, 3.0 mm detector slit; and all measurement conditions are recorded in the instrument control file. The software used for data collection is Diffrac.Commander v4.6. Data analysis is performed using Diffrac.Eva v4.1.1 software. No background correction or smoothing is applied to the patterns.

[0166] Simultaneous Thermogravimetric Analysis (TGA) and Differential Scanning Calorimetry (TGA / DSC) Analysis: TGA / DSC studies are performed using a Mettler Toledo TGA / DSC1 STARe System equipped with a 34-position autosampler, using a 40 μl aluminum crucible with holes. Typically, the crucible contains 5-10 mg of sample, held at 20° C. for 5 minutes, and then heated from 20° C. to 350° C. at 10° C. / min. A nitrogen purge of 40 ml / min is maintained over the sample. The software used for instrument control and data analysis is STARe v15.00. No corrections are applied to the thermograms.

[0167] Further differential scanning calorimetry (DSC) analysis: DSC studies are performed using a Mettler Toledo HP DSC1 equipped with a camera, using 40 μl open aluminum standard pans. Samples are heated from 25° C. to 350° C. at 4° C. / min under 1 bar nitrogen.

[0168] Alternative Thermogravimetric (TG) Analysis: TGA is performed using a Mettler Toledo TGA / SDTA851e using 40 μl open aluminum standard pans. Samples are heated from 25° C. to 350° C. at 4° C. / min under 1 bar nitrogen.

[0169] Fourier transform infrared spectroscopy (FT-IR): FT-IR studies are performed using a Thermo Scientific Nicolet iS50, instrument #2357. Attenuated total reflectance (ATR) technique is used with a KBr beam splitter. The number of scans is 16, with a resolution of 4.000, 400 cm -1 ~4000cm -1 The software OMNIC version 9.2 is used for data collection and evaluation.

[0170] High Performance Liquid Chromatography (HPLC): High performance liquid chromatography analysis is performed on an Agilent 1290 system including a CSH C18 column (50 mm x 2.1 mm; particle size 1.7 μm), degasser, pump, autosampler, thermostat, and DAD type detector operating at 230 nm. The column is run at 35° C. with a flow rate of 1 mL / min for a runtime of 12 min as follows: 2 min gradient A / B 98:2 to 75:25; 6 min gradient A / B 75:25 to 50:50; 2 min gradient A / B 50:50 to 10:90; 2 min at 98:2 A / B. Mobile phase A: Milli-Q water with 0.1% formic acid; Mobile phase B: acetonitrile with 0.1% formic acid. Sample diluent is 50 / 50 methanol / acetonitrile with an injection volume of 2.0 μl.

[0171] Proton Nuclear Magnetic Resonance (NMR): Samples are prepared in DMSO-d6 solvent and spectra are collected on an Agilent Inova400 at room temperature with a frequency of 399.9 MHz, a sweep width of 6398 Hz and spins of 20 Hz.

[0172] (6bR,10aS)-8-(3-(4-fluorophenoxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (compound A) was synthesized and recrystallized as described in WO 2020 / 131895. Compound A is a brown crystalline powder with a melting event at a peak temperature of 145°C. The compound exists as aggregated blocks less than 20 μm in size and is slightly hygroscopic. The compound is only soluble in DMSO. It is sparingly soluble in ethyl salicylate and anisole. It is less than sparingly soluble (less than 11 mg / mL) in 2-butanol, methanol, water, ethyl acetate, heptane and cyclohexane.

[0173] Example 1: Initial salt screening The initial initial salt screen is performed using six solvents (methanol, DMSO, acetone, acetonitrile, ethyl acetate, toluene) and 14 acids. Each experiment is performed using 30 mg of Compound A free base and 800 μL of solvent at a 1:1 molar ratio of the free base to the acid, except for two acids (hydrochloric acid and sulfuric acid) which are tested at both 1:1 and 1:3 molar ratios. The salt screen, including slurry experiments, cooling crystallization, anti-solvent, and shaking slurry experiments, is performed on a Freeslate CM2 instrument.

[0174] Distribute 30 mg of compound A free base into each well of the master plate and shake plate (both in 96-well plate format). Add solid acid followed by solvent, or add the solvent first and then liquid acid. Then heat the master plate to 50° C. and equilibrate at this temperature for 2 hours. Each well is equipped with a stir bar (stirring speed is 500 rpm). After 2 hours, filter the residue and transfer the filtrate to a cooling crystallization plate or precipitation plate.

[0175] The cooled crystallization plate is cooled slowly from 50° C. to 10° C. over 8 hours using an inversed cubic rate. The precipitation plate is filled with water or heptane (300 μl) as anti-solvent (depending on its miscibility with the screening solvent). The shaken slurry plate is shaken at room temperature for 24 hours. All the obtained solids are characterized by XRPD.

[0176] 384 combinations of acids, solvents and methods are tested. The majority result in either no solid being formed, an amorphous solid, or a solid that is identified as Compound A free base or acid. Thirty-one reaction conditions produce crystalline solids that are neither Compound A free base nor acid, and the XRPD of these 31 solids show 20 different patterns.

[0177] These putative salt crystal patterns are obtained using hydrochloric, p-toluenesulfonic, L-tartaric, L-ascorbic, fumaric, sulfuric, acetic, succinic, L-malic, glutamic and citric acids. Experiments using phosphoric, benzoic or maleic acids do not yield XRPD patterns. Successful crystallizations occur in most cases only using acetone, acetonitrile, ethyl acetate or toluene solvents. Most of the positive results are obtained using the slurry or shaking slurry technique.

[0178] Successful experiments are repeated on a slightly larger scale (50 mg) to obtain sufficient material for characterization and salt confirmation. Unexpectedly, only hydrochloric acid, p-toluenesulfonic acid, L-tartaric acid and L-ascorbic acid produced XRPD crystalline salt products on the larger scale, with results varying depending on the solvent and method used: [Table 4]

[0179] A second, third and fourth initial salt screening experiment is performed using the same solvent and a diverse set of acids (44 additional acids are tested, for a total of 768 additional reaction conditions). Several new crystalline XRPD patterns are obtained at the initial screening scale (30 mg), and successful results are repeated at 50 mg for further characterization of the products. At larger scales, only galactaric, oxalic, thiocyanic, orotic and gentisic acids give rise to crystalline salts. However, 1 H-NMR analysis does not confirm the presence of a crystalline solid as a salt of Compound A.

[0180] Example 2: Development of further salt screens Further experiments are performed using some of the successful acid / solvent / process conditions from Example 1 with changes in solvent amount and / or material concentration, and / or changes in the molar ratio of Compound A free base to acid (1:1.2, 1:1.5 or 1:2). Some experiments are further repeated on a 500 mg scale with additional analyses including 1H-NMR, DSC / TGA, and / or FTIR for confirmation of results.

[0181] Crystals of the hydrochloride salt are found to show decomposition by NMR. Confirmed Compound A crystalline salts are found for p-toluenesulfonic acid (1:1, 1:1.5, or 1:2 molar ratios using ethyl acetate or toluene solvents), L-ascorbic acid (1:1 or 1:2 molar ratios using ethyl acetate or acetone solvents), L-tartaric acid (1:1.5 or 1:3 molar ratios using ethyl acetate solvent), and succinic acid (1:2 molar ratio using ethyl acetate solvent). At the 500 mg scale, L-tartaric acid and L-ascorbic acid reliably produce crystalline salts using a 1:2 molar ratio of free base to acid (ethyl acetate or acetone solvents, respectively).

[0182] Further experiments are carried out using the room temperature slurry technique with eight acids (acetic acid, citric acid, fumaric acid, L-ascorbic acid, L-aspartic acid, L-malic acid, L-tartaric acid, succinic acid) and six solvents (toluene, methanol, 2-butanone, benzonitrile, cyclohexane, diisopropyl ether). Positive results are obtained only with fumaric acid / methanol, L-malic acid / methanol, and L-tartaric acid / cyclohexane. The fumarate salt is a brown powder, the maleate salt is a dark brown sticky solid, and the tartrate salt is a light brown powder. Further extensive experiments with fumaric acid, ascorbic acid, and tartaric acid produced reliable salt crystals only for tartaric acid, with the best results obtained using ethyl acetate solvent.

[0183] Further screening experiments are then carried out using tartaric acid, ascorbic acid, fumaric acid, malic acid, hydrochloric acid, p-toluenesulfonic acid, oxalic acid and benzenesulfonic acid in additional solvents (acetonitrile, ethyl acetate, propionitrile, benzonitrile, anisole, butyl acetate, ethyl formate, tetrahydrofuran, cyclopentyl methyl ether, dibutyl ether, acetone, methanol, ethanol, 1-propanol, 2-propanol, 2-butanol, 2-butanone, DMSO, toluene). Each of these experiments is carried out on a 50 mg scale using 1.5 equivalents of acid and 300 μL of solvent. The following positive results are obtained: [Table 5]

[0184] Further experiments are carried out on a 200 mg scale with 1.2 mL of solvent using p-toluenesulfonic acid and oxalic acid. Good results are obtained using acetone or 2-butanone for p-toluenesulfonic acid, and acetone, acetonitrile, ethyl acetate, toluene or 2-butanone for oxalic acid.

[0185] Finally, these experiments are repeated on a 500 mg scale with the following results: [Table 6]

[0186] The XRPD overlay shows that the same p-toluenesulfonate polymorph is formed using both 2-butanone and acetone solvents. The XRPD patterns observed for Experiments 2-A and 2-B are the same as those shown in Figure 1 (from Example 3). 1 The H-NMR spectra are also virtually identical, indicating the formation of a 1:1 free base / acid salt. LCMS indicates a purity of about 92% for salt 2-A and about 88% for salt 2-B. The FTIR spectra are also virtually identical for both products, consistent with the formation of a salt.

[0187] TGA / DSC shows that the two p-toluenesulfonate crystals have similar thermograms with slightly different peak shapes and onset temperatures, which may indicate differences in solvent entrapment in the crystal structures. An overlay of the TGA / DSC thermograms for p-toluenesulfonate crystals 2-B (top) and 2-A (bottom) is shown in Figure 2.

[0188] XRPD overlays show that the same oxalate polymorph is formed with each tested solvent (Runs 2-C through 2-G). Products from Runs 2-E and 2-F are selected for further analysis. 1 H-NMR spectra show that products 2-E and 2-F are essentially the same, indicating the formation of a 1:1 free base / acid salt. LCMS shows a purity of about 88% for salt 2-E and 84% for salt 2-F. FTIR spectra are also essentially the same for both products, consistent with the formation of a salt.

[0189] The XRPD pattern for Run 2-E is shown in Figure 7. The XRPD peak list for Figure 7 is shown below: [Table 7]

[0190] TGA / DSC shows that the two oxalate crystals 2-E and 2-F have thermograms that show similar events, although the peak shapes and onset temperatures are slightly different. This may indicate differences in solvent entrapment in the crystal structures. An overlay of the TGA / DSC thermograms of oxalate crystals 2-F (top) and 2-E (bottom) is shown in Figure 8. The mass loss (approximately 25 wt%) observed in the temperature range of 160 °C to 240 °C may be the decomposition of the oxalate salt.

[0191] These results demonstrate the reproducibility of the formation of the compound Ap-toluenesulfonic acid and oxalate crystalline salts.

[0192] The tosylate salt shows improved solubility (1.2-1.7 mg / mL in water) compared to the oxalate salt (0.2-0.3 mg / mL in water).

[0193] Example 3: Toluenesulfonate scale-up The free base form of (6bR,10aS)-8-(3-(4-fluorophenoxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (1.88 g) is added to a 20 mL vial. 11 mL of 2-butanone is added and the reaction mixture is heated to 50 °C to form a brown suspension. Solid toluenesulfonic acid (1.5 equiv.) is added and the mixture immediately becomes a homogeneous brown solution. With stirring at 50 °C, the product slowly begins to crystallize. After stirring for about 1 hour, the heat is removed and the reaction mixture is allowed to cool to room temperature (overnight) with stirring. A brown suspension is obtained. The mixture is filtered and washed with 2-butanone under vacuum to give 1.7 g of an off-white to brownish powder (about 62% yield). The powder slowly turns purple at room temperature. The XRPD pattern is shown in Figure 1. The XRPD analysis shows the characteristic sharp peaks of well crystalline material, although an amorphous background is also present. 1 H-NMR is consistent with the monotosylate salt (1:1 molar ratio of tolyl protons to free base protons). The XRPD peak list for Figure 1 is shown below: [Table 8]

[0194] The TGA / DSC thermogram of the product is shown in Figure 3. The TGA / DSC shows a gradual mass loss of about 3.7 wt% in the temperature range from 29°C to 198°C. A desolvation phenomenon is observed with a peak temperature of about 84°C, and a melting phenomenon is observed with a peak temperature of about 180°C.

[0195] Example 4: Co-crystal screen Co-crystallization is performed using amino acids as coformers. 18 amino acids and 4 solvents (methanol, DMSO, acetone, acetonitrile) were studied. Saturated solutions of Compound A free base in water and saturated solutions of the coformers in water are prepared and mixed. The maximum concentration is set as 0 mg / mL. The saturated solutions are mixed in a 1:1 ratio (by volume) and the combined solution is shaken at 50 °C for about 16 h. The resulting solids were analyzed by XRPD. If the XRPD showed new patterns, the solids were also characterized by FT-IR.

[0196] Initial results show the formation of new crystalline solids in 24 of the 72 experiments (by XRPD). Crystalline solids are only obtained in experiments with DMSO, acetone or acetonitrile as solvents. FTIR analysis of the obtained solids shows no co-crystal formation in 8 of these experiments, shows co-crystal formation in 12 of these experiments and gives equivocal results in the remaining 4 experiments. Results suggest that co-crystals were formed with cysteine, methionine, phenylalanine, serine, alanine, histidine, glycine and valine. Questionable results were also obtained for lysine and threonine.

[0197] Repeat positive and suspected cocrystal experiments on a 100 mg scale. Prepare saturated solutions of compound A free base in DMSO, acetone, and acetonitrile (maximum concentration 40 mg / mL) and saturated solutions of coformers in water (maximum concentration 40 mg / mL). Mix 1.5 mL of the saturated solution of compound A with 1.5 mL of the saturated solution of coformer and shake at 50 °C for 24 h.

[0198] It turns out that only the experiment with DMSO forms a solid, while the other experiments give clear solutions. However, further analysis of the solids by FTIR and DSC / TGA suggests that they are DMSO solvates rather than cocrystals. The clear solutions were then evaporated to dryness to give solids that were analyzed by XRPD and FTIR. The results are consistent with possible cocrystal formation with alanine (acetone solvent), phenylalanine (acetone or acetonitrile solvent), and histidine (acetone or acetonitrile solvent). Further characterization of the products by DSC / TGA and 1H-NMR confirms the formation of cocrystals for alanine and phenylalanine, but not histidine. The data are shown in the table below: [Table 9]

[0199] Additional experiments are performed with alanine and phenylalanine at 50 mg of compound A free base and a 1:1 molar ratio. Acetone-water (1:1, 2:1, and 3:1) and acetonitrile-water (1:1, 2:1, and 3:1) are tested in an attempt to promote crystallization of the product. The reactants are stirred overnight at 50° C. in 1.2 mL of the solvent mixture. Most of it again appears as a clear solution, but precipitation occurs upon cooling to about 7° C. The solids are analyzed by XRPD. New cocrystal patterns are obtained with both amino acids in most of the solvent mixtures. The data suggests that multiple polymorphic forms are available, but the thermodynamically most stable form has not been determined.

[0200] Example 5: Toluenesulfonate production optimization Further optimization of the process for preparing crystalline Compound A toluenesulfonate salt will be performed. The effects of solvent, stoichiometry and temperature will be evaluated. Considerations include product appearance and morphology (including XRPD), yield, product purity (HPLC, 1 1 H-NMR), as well as residual solvent levels (GC-HS).

[0201] The procedure according to Example 3 is repeated for consistency (Experiment 3-2 in the table below). For other experiments, the following general procedure is used: Compound A in free base form is added to the reactor, then acetone solvent is added. The reactor is brought to the desired initial temperature, then p-toluenesulfonic acid monohydrate solution in acetone is slowly added. The reactor is kept stirred while the temperature is lowered to the desired final temperature. During this time, crystalline product is formed. The resulting mixed suspension is filtered, and the filter cake is washed with acetone solvent and then dried.

[0202] It is found that adding toluenesulfonic acid monohydrate as a solution rather than as a solid, using lower temperatures, and using acetone rather than 2-butanone provide improved results. Some of the results are summarized in the following table: [Table 10]

[0203] The salt products (5-1 to 5-5) obtained under the modified conditions are off-white to pale yellow in color, stable in air, and do not discolor. The salts are tested under accelerated aging conditions at 70 °C for 3 hours to confirm their chemical stability.

[0204] In further experiments, the reaction volume is increased. It is found that washing the initially formed filter cake with cold acetone solvent, with a final temperature of 5°C, gives improved results. The test includes HPLC analysis for the presence of the synthetic reagent 1-(3-chloropropoxy)-4-fluorobenzene. Further results are summarized in the following table. [Table 11]

[0205] The optimized procedure is then carried out on a 90 g scale in a 1 L reactor equipped with a mechanical stirrer and thermometer under nitrogen atmosphere. 90 g of compound A free base (recrystallized from acetone-methanol) is suspended in 330 mL of acetone at 10 °C. A solution of p-toluenesulfonic acid in acetone (0.98 equiv; 32.98 g in 120 mL of acetone) is added dropwise while maintaining the reactor temperature at 10-15 °C. The total volume of acetone is 450 mL (0.2 g / mL for compound A free base). The reaction is stirred at about 10 °C for 16 h. The precipitated crystalline product is filtered and the filter cake is washed with acetone (3 × 110 mL). The product is dried under vacuum at 50 °C to give 118.2 g of product (90.5% yield).

[0206] The product obtained from this procedure is tested using ESI / LCMS, 1D and 2D NMR, elemental analysis, HPLC, FTIR, XRPD, single crystal XRD, DSC, TGA, and a complete impurity analysis including process related impurities, heavy metals and solvents. All test results are consistent with the desired product of high purity. Single crystal X-ray diffraction shows that the crystals have a monoclinic morphology. Figure 4 shows the XRPD spectrum of the product from a 90 g scale reaction. The peak list for the XRPD spectrum in Figure 4 is shown in the table below:

[0207] [Table 12]

[0208] Figures 5 and 6 show the DSC and TGA thermograms, respectively, from the 90 g scale reaction. The DSC thermogram shows a first endothermic event starting at 163°C, which overlaps with a fast exothermic event (solid-solid change based on the camera image). The shape of this endothermic-exothermic curve is consistent with melting and then rapid recrystallization. The TGA test shows no mass loss in this temperature range, consistent with recrystallization. A second endothermic event (melting) is seen between 209°C and 230°C (peak at 226°C; heat: -61 J / g). At higher temperatures, starting at 254°C, a further exothermic event (decomposition) is detected. Because the product phase transitions are incongruent, the melting point is taken as the onset of melting (163°C). The TGA shows a single-stage mass loss starting at 250°C.

[0209] This 90 g scale procedure is carried out on a 190 g scale in a 2 L reactor equipped with a mechanical stirrer and a thermometer under nitrogen atmosphere. On a larger scale, a relatively large amount of acetone is used to suspend Compound A free base and a smaller amount of acetone is used for p-toluenesulfonic acid. Cooling crystallization and drying conditions are also improved.

[0210] 190 g of compound A free base (recrystallized from acetone-methanol) is suspended in 1700 mL of acetone at 10 °C. A solution of p-toluenesulfonic acid in acetone (0.98 equivalents; 92.85 g in 200 mL of acetone) is added dropwise while maintaining the reactor temperature at 10-15 °C. The total volume of acetone is 1900 mL (0.1 g / mL for compound A free base). The reaction is stirred at about 10 °C for 3 hours, then cooled to 5 °C over 1.5 hours, and then stirred at 5 °C for 8 hours. The precipitated crystalline product is filtered and the filter cake is washed with acetone (3 x 200 mL). The product is dried under vacuum at 40 °C, giving 249.5 g of product (90.5% yield). Characterization of the two products provides the following information: [Table 13]

[0211] The 190 g scale procedure is successfully repeated at a scale of 5.2 kg of Compound A free base in a 160 L glass-lined reactor. At this larger scale, additional acetone is used to rinse the reactor feed lines, but the final concentration is the same at 0.1 g / mL. The addition of p-toluenesulfonic acid is done over approximately 40 minutes at 10-15°C, then allowed to stir for 3 hours, cooled to 5°C (over approximately 1.5-2 hours), and stirred at 5°C for 14 hours. Drying is done under vacuum at temperatures up to 40°C. The net yield is 78%, which is mainly due to product losses on the reactor walls and filter dryer. The following analytical results are obtained for the product:

[0212] [Table 14]

[0213] The above examples are intended to illustrate the present invention and should not be construed as limiting the present invention.

[0214] All documents cited above are hereby incorporated by reference in their entirety.

Claims

Claim 1: A salt of (6bR,10aS)-8-(3-(4-fluorophenoxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (Compound A) in solid crystalline form, wherein the salt form is the p-toluenesulfonate salt and the salt is chemically stable in air. Claim 2 The salt has a crystal structure characterized by an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8 peaks with angle (2θ) values selected from the group consisting of about 5.9, 8.6, 11.4, 13.6, 14.9, 17.0, 19.4, 20.0, 20.9, 22.6, 23.8, 24.6, 25.3, 25.6, 25.9, 27.5, 28.0, 29.0, 29.9, 32.5, 33.6, 36.6, 36.6 and 36.6, taking into account potential variations due to sample purity and instrument fluctuations. For example, the X-ray powder diffraction pattern is generated using an X-ray diffractometer equipped with a copper anode and a nickel filter. The salt according to claim 1. Claim 3: A salt of (6bR,10aS)-8-(3-(4-fluorophenoxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (Compound A) in solid crystalline form, wherein the salt form is selected from hydrochloride, tartrate, malate, fumarate, glutamate, oxalate, besylate and ascorbate. Claim 4 The salt according to any one of claims 1 to 3, wherein the salt has a purity of at least 98%. Claim 5 The salt according to any one of claims 1 to 3, wherein the salt contains less than 1% by weight of Compound A in free base form. Claim 6 The salt according to any one of claims 1 to 3, wherein the salt contains less than 1% by weight of p-toluenesulfonic acid, tartaric acid, malic acid, fumaric acid, glutamic acid, oxalic acid or ascorbic acid.

7. The salt according to any one of claims 1 to 3, wherein the salt contains less than 0.5% by weight, or less than 0.1% by weight, of a synthetic precursor of the synthetic method used to prepare the compound A in free base form or a by-product from the synthetic method.

8. The salt according to any one of claims 1 to 3, wherein the salt contains less than 5000 ppm of total residual solvent.

9. The salt according to any one of claims 1 to 3, wherein the salt contains less than 100 ppm of 1-(3-chloropropoxy)-4-fluorobenzene.

10. The salt according to any one of claims 1 to 3, wherein the salt contains less than 1% by weight of water.

11. The salt according to any one of claims 1 to 3, wherein the salt contains less than 100 ppm of an alkyl p-toluenesulfonate (for example, methyl ester, ethyl ester and / or isopropyl ester).

12. A method for producing (6bR,10aS)-8-(3-(4-fluorophenoxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (Compound A) in solid crystalline p-toluenesulfonate form, comprising: (a) reacting the free base of (6bR,10aS)-8-(3-(4-fluorophenoxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (Compound A) with p-toluenesulfonic acid and an organic solvent containing acetone; and (b) recovering the salt thus formed. A method comprising **Claim 13** A method for producing the salt according to claim 3, comprising: (a) reacting the free base of (6bR,10aS)-8-(3-(4-fluorophenoxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (Compound A) with an acid selected from hydrochloric acid, tartaric acid, malic acid, fumaric acid, glutamic acid, oxalic acid, benzenesulfonic acid and ascorbic acid, together with, for example, an organic solvent; and (b) recovering the salt thus formed. A method comprising **Claim 14** A cocrystal of (6bR,10aS)-8-(3-(4-fluorophenoxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (Compound A) in solid form. **Claim 15** The cocrystal according to claim 14, wherein the cocrystal is a cocrystal with an amino acid (for example, a natural α-amino acid), and for example, the amino acid is selected from alanine, cysteine, methionine, phenylalanine, serine, glycine, histidine and valine. **Claim 16** A method for producing the cocrystal according to claim 14 or 15, comprising: (a) Reacting the free base of (6bR,10aS)-8-(3-(4-fluorophenoxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (Compound A) with a co-crystallizing agent optionally selected from amino acids such as alanine, asparagine, cysteine, methionine, phenylalanine, proline, serine, glutamine, glycine, histidine, lysine, threonine, tyrosine and valine (e.g., alanine or phenylalanine), and, for example, an organic solvent (e.g., methanol, dimethyl sulfoxide, acetone or acetonitrile, e.g., selected from acetone or acetonitrile); and (b) Recovering the co-crystal thus formed A method comprising the above.

17. A pharmaceutical composition comprising a salt according to any one of claims 1 to 3, or a co-crystal according to claim 14 or 15, in combination or association with a pharmaceutically acceptable diluent or carrier.

18. 5-HT 2A receptor, serotonin transporter (SERT), dopamine D 1 / D 2 receptor signaling pathway, and / or a pharmaceutical composition comprising a salt according to any one of claims 1 to 3 or a co-crystal according to claim 14 or 15 for the prevention or treatment of a human suffering from a disease or disorder in which the μ-opioid receptor is involved or intervenes.

19. The disease or abnormal condition is selected from obesity, anxiety, depression (e.g., treatment-resistant depression and MDD), psychosis (including psychosis associated with dementia such as hallucinations or paranoid delusions in progressive Parkinson's disease), schizophrenia, sleep disorders (especially sleep disorders associated with schizophrenia and other mental and neurological diseases), sexual disorders, migraine, headache-related conditions, social phobia, agitation in dementia (e.g., agitation in Alzheimer's disease), agitation in autism and related autistic disorders, gastrointestinal disorders such as gastrointestinal motility dysfunction, and dementia, e.g., dementia in Alzheimer's disease or dementia in Parkinson's disease; mood disorders; and drug dependence, e.g., opioid dependence or opioid use disorder, and / or alcohol dependence, or withdrawal from drug dependence or alcohol dependence (e.g., opioid dependence or opioid use disorder); or binge eating disorder; or, opioid overdose or opioid use disorder; or opioid use disorder (OUD); or substance use disorder or substance abuse disorder (e.g., as defined in DSM-V) (even in patients who also suffer from anxiety and / or depression), the pharmaceutical composition according to claim 18.

20. The disease or abnormal condition is obsessive-compulsive disorder (OCD), obsessive-compulsive personality disorder (OCPD), generalized anxiety disorder, social anxiety disorder, panic disorder, agoraphobia, compulsive gambling disorder, compulsive eating disorder, body dysmorphic disorder, psychosis, pathological grooming disorder, kleptomania, pyromania, attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), impulse control disorder, and related disorders, and combinations thereof; or a pain disorder, e.g., a pain-related condition, e.g., headache, idiopathic pain, neuropathic pain, chronic pain (e.g., moderate to moderately severe chronic pain in patients requiring continuous 24-hour treatment for another disease, for example), fibromyalgia, toothache, trauma pain or chronic fatigue; or, here, the central nervous system disease or disorder is drug addiction (e.g., opioid addiction or opioid use disorder (i.e., opioid use disorder), cocaine addiction, amphetamine addiction, and / or alcohol addiction), or withdrawal from drug addiction or alcohol addiction (e.g., opioid addiction, opioid use disorder, cocaine addiction or amphetamine addiction), the patient also suffers from co-existing conditions such as anxiety, depression or psychosis, and / or the patient also suffers from opioid overdose or opioid overdose, the pharmaceutical composition according to claim 18.

21. The patient suffers from an existing or co-existing gastrointestinal disorder and / or lung disorder, e.g., the existing or co-existing disorder is selected from the group consisting of irritable bowel syndrome, pelvic floor disorder, diverticulitis, inflammatory bowel disease, colon cancer or colorectal cancer, celiac disease, non-celiac gluten sensitivity, asthma, chronic obstructive pulmonary disease (COPD), dyspnea, pneumonia, congestive heart failure, interstitial lung disease, pneumothorax, bronchitis, pulmonary embolism, and traumatic chest injury (e.g., fracture of the sternum or rib, intercostal muscle contusion), the pharmaceutical composition according to claim 18.

Images